UBS analyst UBS maintained a Hold rating on Agilent Technologies (NYSE:A) on Monday, setting a price target of $87, which is approximately 2.38% above the present share price of $84.98.
expects Agilent Technologies to post earnings per share (EPS) of $0.33 for the second quarter of 2020.
The current consensus among 11 TipRanks analysts is for a Moderate Buy rating of shares in Agilent, with an average price target of $88.8.
The analysts price targets range from a high of $95 to a low of $76.
In its latest earnings report, released on 04/30/2020, the company reported a quarterly revenue of $1.24 billion and a net profit of $102 million. The company's market cap is $26.53 billion.
According to TipRanks.com, UBS analyst UBS is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 5.8% and a 58.36% success rate.
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment comprises activity providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software, and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.